Crizanlizumab in Sickle Cell Disease

Kenneth Ataga, Abdullah Kutlar, Julie Kanter

Research output: Contribution to journalLetter

4 Citations (Scopus)
Original languageEnglish (US)
Number of pages1
JournalThe New England journal of medicine
Volume376
Issue number18
DOIs
StatePublished - May 4 2017
Externally publishedYes

Fingerprint

Sickle Cell Anemia

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Crizanlizumab in Sickle Cell Disease. / Ataga, Kenneth; Kutlar, Abdullah; Kanter, Julie.

In: The New England journal of medicine, Vol. 376, No. 18, 04.05.2017.

Research output: Contribution to journalLetter

Ataga, Kenneth ; Kutlar, Abdullah ; Kanter, Julie. / Crizanlizumab in Sickle Cell Disease. In: The New England journal of medicine. 2017 ; Vol. 376, No. 18.
@article{880836f94ea94720aee1763fb721b146,
title = "Crizanlizumab in Sickle Cell Disease",
author = "Kenneth Ataga and Abdullah Kutlar and Julie Kanter",
year = "2017",
month = "5",
day = "4",
doi = "10.1056/NEJMc1703162",
language = "English (US)",
volume = "376",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "18",

}

TY - JOUR

T1 - Crizanlizumab in Sickle Cell Disease

AU - Ataga, Kenneth

AU - Kutlar, Abdullah

AU - Kanter, Julie

PY - 2017/5/4

Y1 - 2017/5/4

UR - http://www.scopus.com/inward/record.url?scp=85044534502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044534502&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1703162

DO - 10.1056/NEJMc1703162

M3 - Letter

VL - 376

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 18

ER -